At Alveo we understand the importance of access to cutting-edge molecular testing and cloud-based data analytics for rapid diagnosis and management of infectious diseases. With an initial focus on acute respiratory infections including COVID-19, Flu A/B and RSV, Alveo’s agile and dynamic molecular diagnostic platform, be.well™, can be adapted to detect a wide range of diseases, bacteria, and other pathogens, including those in markets and channels beyond clinical diagnostics. We believe increased access to real-time test results will transform the way individuals, healthcare providers, and public health professionals identify and manage infectious diseases.